Silo Pharma, Inc. has entered into an agreement with Frontage Laboratories, a CRO (contract research organization), providing integrated, science-driven, product development services throughout the drug discovery and development process that enable life science companies to achieve their drug development goals.
Frontage has worked with innovators and consumer health companies of all sizes to file IND, NDA, ANDA, BLA, and 505(b)(2) submissions in global markets allowing for the successful development of important patient therapies. The Pharmacokinetic Study in animals will be dose analyzed along with a full analysis of plasma samples.
Eric Weisblum, CEO of Silo Pharma stated, “This agreement significantly advances our Central Nervous System Peptide, SPU-16, and our Joint Homing Peptide, SPU-21 technologies closer to the clinic. These solutions have the potential to enhance the therapeutic effect of current and future therapeutics while decreasing potential systemic toxicity. These peptides also have the potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. They may be used to treat both Central Nervous System and Autoimmune Diseases.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!